Ignite Creation Date:
2025-12-25 @ 2:15 AM
Ignite Modification Date:
2026-01-23 @ 5:43 PM
Study NCT ID:
NCT04701060
Status:
COMPLETED
Last Update Posted:
2024-12-03
First Post:
2021-01-04
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
OBU-TJ-HCC-II-004
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None